SCHEMBL5115874

SCHEMBL5115874

C=CC[C@@](NC(=O)OCc1ccccc1)(C(=O)NCC(=O)OC)C(C)CC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CTSS P25774 3/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
SYK P43405 1/20 0.41
CTSL P07711 2/20 0.40
CTSB P07858 1/20 0.40
HTT P42858 2/20 0.39
TGM2 P21980 1/20 0.39
LMNA P02545 1/20 0.39
MBOAT4 Q96T53 1/20 0.38
CA1 P00915 3/20 0.38
CA2 P00918 3/20 0.38
ACHE P22303 3/20 0.38
CTSK P43235 1/20 0.38
MAPT P10636 2/20 0.38
CYP3A4 P08684 1/20 0.38
TSHR P16473 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
NPBWR1 P48145 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14266062 1.00 CTSS (0.43) CTSSMEN1KMT2ASYKCTSL
SCHEMBL5115478 0.93 CTSS (0.44) CTSSMEN1KMT2ASYKCTSL
SCHEMBL14266053 0.87 CTSK (0.44) CTSSMEN1KMT2ASYKCTSL
SCHEMBL5117346 0.87 CTSK (0.44) CTSSMEN1KMT2ASYKCTSL
SCHEMBL14619533 0.73 MEN1 (0.42) CTSSMEN1KMT2ASYKCTSL
SCHEMBL2065470 0.73 SMN1; SMN2 (0.59) CTSSMEN1KMT2ACTSLCTSB
SCHEMBL7749573 0.72 SMN1; SMN2 (0.51) CTSSMEN1KMT2ASYKCTSL
SCHEMBL22469527 0.70 CTSS (0.50) CTSSMEN1KMT2ASYKCTSL
SCHEMBL24822539 0.70 CTSS (0.50) CTSSMEN1KMT2ASYKCTSL
SCHEMBL22648546 0.70 CTSS (0.50) CTSSMEN1KMT2ASYKCTSL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7338974-B2 Macrocyclic diaminopropanes as beta-secretase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2008-03-04 US disclosed
WO-2007021793-A1 MACROCYCLIC DIAMINOPROPANES AS BETA-SECRETASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-02-22 WO disclosed
US-20070037868-A1 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome BRISTOL-MYERS SQUIBB COMPANY 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037868-A1 5-Benzyl-4-hydroxy-18-methoxy-8-(2-oxo-pyrrolidin-1-yl)-13-oxa-2,6-diaza-tricyclo[12.6.1.015,20]henicosa-10,15(20),16,18-tetraen-7-one; Alzheimer's Disease; Down's Syndrome APP, BACE1, PSEN1 CTSS 86/4885MEN1 2986/4885KMT2A 3539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.